441 material Form 8-K filings that 376 companies we cover made with the SEC in June 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
PVH reported first quarter revenue of $1.984 billion, up 2% and above its guidance, but posted a GAAP loss of $(0.88) per share after a $480 million noncash impairment charge. The company reaffirmed its full-year revenue outlook but lowered its non-GAAP EPS projection to $10.75 to $11.00 from $12.40 to $12.75, citing tariffs and a challenging consumer backdrop.
Q1 revenue rose 2% to $1.984 billion, above guidance of flat to a 2% decrease.
Q1 GAAP EPS was $(0.88); non-GAAP EPS was $2.30, above guidance of $2.10 to $2.25.
Full-year non-GAAP EPS outlook cut to $10.75 to $11.00 from $12.40 to $12.75; revenue outlook reaffirmed.
Projected full-year non-GAAP operating margin is about 8.5%, versus 10.0% in 2024; tariffs carry an unmitigated impact of about $1.05 per share.
ANI Pharmaceuticals filed its investor presentation for the Jefferies Global Healthcare Conference, where CEO Nikhil Lalwani will speak on June 4, 2025. The slides restate 2025 guidance issued on May 9, 2025, which the company describes as its second guidance raise of the year, and they report first-quarter 2025 revenue and profit growth. The filing presents previously disclosed figures rather than new results, but the guidance increase is relevant to shareholders.
2025 net revenue guidance is $768 million to $793 million, up from $756 million to $776 million previously.
2025 adjusted non-GAAP EBITDA guidance is $195 million to $205 million, up from $190 million to $200 million; adjusted diluted EPS guidance is $6.27 to $6.62, up from $6.12 to $6.49.
First-quarter 2025 total revenue was $197 million, up 43% year over year, and adjusted non-GAAP EBITDA was $51 million, up 35%.
Q1 ILUVIEN and YUTIQ revenue of $16 million was temporarily affected by factors the company listed, including sales force turnover; the company said demand accelerated in Q2 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.